<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="45011745-b15e-49d0-adea-8a8946860566"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>PLASMA-LYTE 148 Injection (Multiple Electrolytes <br/> Injection, Type 1, USP)<br/>in VIAFLEX Plastic Container</title>
   <effectiveTime value="20190805"/>
   <setId root="7eee0bda-06d8-4cc4-85e9-7c6e4801f09c"/>
   <versionNumber value="13"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Company</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
                  <name>Baxter Healthcare Corporation</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="059140764" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0179" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0179" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0179" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0179" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0179" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194684502" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0179" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="d499c854-ceb1-47c8-bb15-798c9a47ecb4"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20170828"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-0179" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Plasma-Lyte 148</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="526"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q32ZN48698" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CHLORIDE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="502"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="R6Q3791S76" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM GLUCONATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="R4R8J0Q44B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GLUCONIC ACID</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="368"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="569DQM74SC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ACETATE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="37"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q32ZN48698" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CHLORIDE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="T6V3LHY838" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q32ZN48698" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CHLORIDE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0179-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19790202"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0179-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19790202"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA017378" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19790202"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_inv-f855447e-cfb1-420f-87e0-ae5416f2a308">
               <id root="23afc9d9-f677-4ef2-bee9-2757187326e8"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C<sub>6</sub>H<sub>11</sub>NaO<sub>7</sub>); 368 mg of Sodium Acetate Trihydrate, USP (C<sub>2</sub>H<sub>3</sub>NaO<sub>2</sub>•3H<sub>2</sub>O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl<sub>2</sub>•6H<sub>2</sub>O). It contains no antimicrobial agents. The pH is adjusted with hydrochloric acid. The pH is 5.5 (4.0 to 8.0).</paragraph>
                  <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 140 mEq sodium, 5 mEq potassium, 3 mEq magnesium, 98 mEq chloride, 27 mEq acetate, and 23 mEq gluconate. The osmolarity is 294 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. The caloric content is 21 kcal/L.</paragraph>
                  <paragraph>The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.</paragraph>
               </text>
               <effectiveTime value="20130911"/>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_inv-074349dd-a802-4a78-abb5-e89b36e87d64">
               <id root="af0aaeef-a106-496c-b647-ac1d229c1e05"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) has value as a source of water and electrolytes. It is capable of inducing diuresis depending on the clinical condition of the patient.</paragraph>
                  <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) produces a metabolic alkalinizing effect. Acetate and gluconate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations.</paragraph>
               </text>
               <effectiveTime value="19790202"/>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_inv-c1387527-e80b-42a0-bda5-e7974b86c7a5">
               <id root="1777a9c9-608c-4abb-97bb-46b8bb151e29"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is indicated as a source of water and electrolytes or as an alkalinizing agent.</paragraph>
               </text>
               <effectiveTime value="20190805"/>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_inv-397e5aa0-123d-45a3-9c68-d2661ff3539a">
               <id root="1ec909b1-2067-4ca6-926d-17e6f3a64916"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is contraindicated in patients with a known hypersensitivity to the product. See <content styleCode="bold">
                        <linkHtml href="#i4i_warnings_id_inv-eb0d5b5b-321c-4367-ad93-739fb065dd19">WARNINGS</linkHtml>
                     </content>.</paragraph>
               </text>
               <effectiveTime value="20190805"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_id_inv-eb0d5b5b-321c-4367-ad93-739fb065dd19">
               <id root="f374524d-d737-405b-849e-4080e7991ada"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <effectiveTime value="20190805"/>
               <component>
                  <section ID="ID_1ed43f85-91fe-49bf-9dd3-998e67e40f82">
                     <id root="b20c9885-5793-41f3-92c0-99dbd2e400db"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>Hypersensitivity and infusion reactions have been reported with PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP). See <content styleCode="bold">
                              <linkHtml href="#i4i_adverse_effects_id_inv-c1a8c4d6-5a32-4f08-af70-41d52b1013f7">ADVERSE REACTIONS</linkHtml>
                           </content>.</paragraph>
                        <paragraph>Stop the infusion immediately if signs or symptoms of a hypersensitivity reaction develop, such as tachycardia, chest pain, dyspnea and flushing.  Institute appropriate therapeutic countermeasures as clinically indicated. </paragraph>
                     </text>
                     <effectiveTime value="20190805"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_27ad6608-7852-4e97-9b16-26b87f273262">
                     <id root="af4474d3-a913-4a58-9fa4-ea675a2167e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Electrolyte Imbalances </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Fluid Overload</content>
                        </paragraph>
                        <paragraph>Depending on the volume and rate of infusion, the intravenous administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) can cause electrolyte disturbances such as overhydration and congested states, including pulmonary congestion and edema. </paragraph>
                        <paragraph>Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with or at risk for fluid and/or solute overloading.  If use cannot be avoided, monitor fluid balance, electrolyte concentrations, and acid base balance, as needed and especially during prolonged use.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hyponatremia</content>
                        </paragraph>
                        <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy, and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury.</paragraph>
                        <paragraph>The risk of hospital-acquired hyponatremia is increased in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH) treated with high volume of hypotonic PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP).</paragraph>
                        <paragraph>Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in hypervolemic or overhydrated patients. If use cannot be avoided, monitor serum sodium concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypernatremia</content>
                        </paragraph>
                        <paragraph>Hypernatremia may occur with PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP).  Conditions that may increase the risk of hypernatremia, fluid overload and edema (central and peripheral), include patients with: primary hyperaldosteronism; secondary hyperaldosteronism associated with, for example, hypertension, congestive heart failure, liver disease (including cirrhosis), renal disease (including renal artery stenosis, nephrosclerosis); and pre-eclampsia.</paragraph>
                        <paragraph>Certain medications, such as corticosteroids or corticotropin, may also increase risk of sodium and fluid retention, see <content styleCode="bold">
                              <linkHtml href="#i4i_precautions_id_inv-b4b9873c-c383-4f8d-bdcb-6b0c69546b9a">PRECAUTIONS</linkHtml>
                           </content>.</paragraph>
                        <paragraph>Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with, or at risk for, hypernatremia. If use cannot be avoided, monitor serum sodium concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypermagnesemia</content>
                        </paragraph>
                        <paragraph>Avoid solutions containing magnesium, including PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with or predisposed to hypermagnesemia, including patients with severe renal impairment and those patients receiving magnesium therapy (e.g., treatment of eclampsia and myasthenia gravis). </paragraph>
                        <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is not indicated for the treatment of hypomagnesemia. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Acidosis</content>
                        </paragraph>
                        <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is not for use for the treatment of lactic acidosis or severe metabolic acidosis in patients with severe liver and/or renal impairment.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Alkalosis</content>
                        </paragraph>
                        <paragraph>Excess administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) can result in metabolic alkalosis. Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with alkalosis or at risk for alkalosis. </paragraph>
                        <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is not indicated for the treatment of hypochloremic hypokalemic alkalosis.  Avoid use in patients with hypochloremic hypokalemic alkalosis. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypocalcemia</content>
                        </paragraph>
                        <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) contains no calcium, and an increase in plasma pH due to its alkalinizing effect may lower the concentration of ionized (not-protein bound) calcium. Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with hypocalcemia.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hyperkalemia</content>
                        </paragraph>
                        <paragraph>Potassium-containing solutions, including PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) may increase the risk of hyperkalemia. </paragraph>
                        <paragraph>Patient’s at increased risk of developing hyperkalemia include those:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>With conditions predisposing to hyperkalemia and/or associated with increased sensitivity to potassium, such as patients with severe renal impairment, acute dehydration, extensive tissue injury or burns, certain cardiac disorders such as congestive heart failure.</item>
                           <item>
                              <caption>•</caption>Treated concurrently or recently with agents or products that cause or increase the risk of hyperkalemia (see <content styleCode="bold">
                                 <linkHtml href="#i4i_precautions_id_inv-b4b9873c-c383-4f8d-bdcb-6b0c69546b9a">PRECAUTIONS</linkHtml>
                              </content>). </item>
                        </list>
                        <paragraph>Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with, or at risk for hyperkalemia If use cannot be avoided, monitor serum potassium concentrations.</paragraph>
                        <paragraph>Although PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) has a potassium concentration similar to the concentration in plasma, it is insufficient to produce a useful effect in case of severe potassium deficiency; therefore, it is not indicated for correction of severe potassium deficiency.</paragraph>
                     </text>
                     <effectiveTime value="20190805"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_precautions_id_inv-b4b9873c-c383-4f8d-bdcb-6b0c69546b9a">
               <id root="fa2cc395-2f1a-42b9-8573-513e76639f54"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20190805"/>
               <component>
                  <section ID="ID_c0b93e54-5847-4a93-b547-ed2ff6b84ef9">
                     <id root="e4ac2f00-4d66-49ea-b8df-eef8f5d08697"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Patients with Renal Impairment </title>
                     <text>
                        <paragraph>In patients with renal impairment, administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) may result in sodium and/or potassium or magnesium retention (see <content styleCode="bold">
                              <linkHtml href="#i4i_warnings_id_inv-eb0d5b5b-321c-4367-ad93-739fb065dd19">WARNINGS</linkHtml>
                           </content>). Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with severe renal impairment or conditions that may cause sodium and/or potassium retention or magnesium retention, fluid overload, or edema. If use cannot be avoided, monitor patients with severe renal impairment for development of these adverse reactions.</paragraph>
                     </text>
                     <effectiveTime value="20190805"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_drug_interaction_id_360e462a-c379-4fb3-bb4e-4fe641771125">
                     <id root="c14e55a8-592a-41b3-8df6-2d82eb31138f"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Other Products that Affect Fluid and/or Electrolyte Balance</content>
                        </paragraph>
                        <paragraph>Administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) to patients treated concomitantly with drugs associated with sodium and fluid retention may increase the risk of hypernatremia and volume overload.  Avoid use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients receiving such products, such as corticosteroids or corticotropin.  If use cannot be avoided, monitor serum electrolytes, fluid balance and acid-base balance. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Drugs that Increase the Risk of Hyponatremia</content>
                        </paragraph>
                        <paragraph>Administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients treated concomitantly with medications associated with hyponatremia may increase the risk of developing hyponatremia.</paragraph>
                        <paragraph>Avoid use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients receiving products, such as diuretics, and certain antiepileptic and psychotropic medications. Drugs that increase the vasopressin effect reduce renal electrolyte free water excretion and may also increase the risk of hyponatremia following treatment with intravenous fluids. If use cannot be avoided, monitor serum sodium concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Lithium</content>
                        </paragraph>
                        <paragraph>Renal clearance of lithium may be increased during administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP). Monitor serum lithium concentrations during concomitant use. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Products that Increase the Risk of Hyperkalemia</content>
                        </paragraph>
                        <paragraph>Because of its potassium content, avoid use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients receiving products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine. If use cannot be avoided, monitor serum potassium concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drugs with pH Dependent Renal Elimination </content>
                        </paragraph>
                        <paragraph>Due to its alkalinizing effect (formation of bicarbonate), PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) may interfere with the elimination of drugs with pH dependent renal elimination. Renal clearance of acidic drugs may be increased.  Renal clearance of alkaline drugs may be decreased.</paragraph>
                     </text>
                     <effectiveTime value="20190805"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_drug_lab_interaction_id_inv-2575d0f8-ead1-43ea-9b45-3c9fd3e0d724">
                     <id root="54a6b4a9-ce5b-4a39-9635-7afd34cfe486"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>There have been reports of positive test results using the Bio-Rad Laboratories Platelia <content styleCode="italics">Aspergillus</content> EIA test in patients receiving Baxter gluconate containing PLASMA-LYTE solutions. These patients were subsequently found to be free of <content styleCode="italics">Aspergillus</content> infection.  Therefore, positive test results for this test in patients receiving Baxter gluconate containing PLASMA-LYTE solutions should be interpreted cautiously and confirmed by other diagnostic methods.</paragraph>
                     </text>
                     <effectiveTime value="20190805"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_b61fc1f0-3b35-47f8-ba67-17e651a9c0e4">
                     <id root="572b2e2a-d8f8-4a92-ad8a-6378329570fb"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Studies with PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.</paragraph>
                     </text>
                     <effectiveTime value="20130911"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pregnancy_id_26835790-7f54-4066-8cf3-3cfcf95d58f9">
                     <id root="952f322b-bbfd-43bf-bf83-dd7f85251bca"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20190805"/>
                     <component>
                        <section ID="ID_85BBFC38-537D-42F2-BDF9-A0F1B94469D5">
                           <id root="35dcd18d-691b-4845-953c-4781cc90460e"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>Teratogenic Effects</title>
                           <text>
                              <paragraph>Animal reproduction studies have not been conducted with PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP). It is also not known whether PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) should be given to a pregnant woman only if clearly needed.</paragraph>
                           </text>
                           <effectiveTime value="20190805"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_8023fada-e4e4-4073-b25a-7aa450011ffe">
                     <id root="0184e136-9785-450d-91f8-9fa95a7aa330"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known where this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is administered to a nursing mother.</paragraph>
                     </text>
                     <effectiveTime value="20130911"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_a1c336a7-1a68-4fa8-a61c-0416c22c0390">
                     <id root="532d69e5-1a6d-4e43-b129-d7d27ac71066"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>The use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in pediatric patients is based on clinical practice.</paragraph>
                     </text>
                     <effectiveTime value="20130911"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_9e461361-4755-41e0-8a44-72103806f5ec">
                     <id root="430feb2d-d966-4d45-9ce3-b599a0e8c08f"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Geriatric patients are at increased risk of developing electrolyte imbalances.  PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Consider monitoring renal function in elderly patients</paragraph>
                     </text>
                     <effectiveTime value="20190805"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_inv-c1a8c4d6-5a32-4f08-af70-41d52b1013f7">
               <id root="6fb2d673-b69b-4e5b-97e6-1d54cb753d38"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <effectiveTime value="20190805"/>
               <component>
                  <section ID="i4i_section_id_17924087-3064-4114-a4f2-071192c09854">
                     <id root="56bc292d-634a-4f25-b708-5b71aac5f56c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Post-marketing Adverse Reactions</title>
                     <text>
                        <paragraph>The following adverse reactions associated with the use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) were identified in clinical trials or postmarketing reports. Because postmarketing reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure.<br/>
                           <br/>
                           <content styleCode="italics">Hypersensitivity and Infusion Reactions</content>: tachycardia, palpitations, chest pain, chest discomfort, dyspnea, flushing, hyperemia, asthenia, feeling abnormal, piloerection, edema peripheral, pyrexia, hypotension, wheezing, urticaria, cold sweat, chills.<br/>
                           <br/>
                           <content styleCode="italics">General Disorders and Administration Site Conditions</content>:  infusion site pain, burning sensation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and nutrition disorders</content>: hyperkalemia, hyponatremia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders</content>: hyponatremic encephalopathy.</paragraph>
                     </text>
                     <effectiveTime value="20190805"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_overdosage_id_f37ba1be-1730-4ab0-aad2-8cb8b146b1f0">
                     <id root="78bc72e5-1346-4f54-aeba-c51c2c153ad0"/>
                     <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
                     <title>Overdose</title>
                     <text>
                        <paragraph>Excessive administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) can cause:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>fluid overload with a risk of edema (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired. </item>
                           <item>
                              <caption>•</caption>hypernatremia and hyperkalemia, especially in patients with severe renal impairment. </item>
                           <item>
                              <caption>•</caption>hypermagnesemia.  See <content styleCode="bold">
                                 <linkHtml href="#i4i_warnings_id_inv-eb0d5b5b-321c-4367-ad93-739fb065dd19">WARNINGS</linkHtml>
                              </content> and <content styleCode="bold">
                                 <linkHtml href="#i4i_adverse_effects_id_inv-c1a8c4d6-5a32-4f08-af70-41d52b1013f7">ADVERSE REACTIONS</linkHtml>
                              </content>
                           </item>
                           <item>
                              <caption>•</caption>metabolic alkalosis with or without hypokalemia and decreased ionized serum calcium and magnesium concentrations. </item>
                        </list>
                        <paragraph>When assessing an overdose, any additives in the solution must also be considered. </paragraph>
                        <paragraph>The effects of an overdose may require immediate medical attention and treatment. </paragraph>
                        <paragraph>Interventions include discontinuation of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP), dose reduction, and other measures as indicated for the specific clinical constellation (e.g., monitoring of fluid balance, electrolyte concentrations and acid base balance).</paragraph>
                     </text>
                     <effectiveTime value="20190805"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_inv-23b70429-45d8-4d08-8ccc-d454e92b4cbc">
               <id root="a7bdd7ca-3e93-4d04-9bc8-a42aa2589967"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Important Administration Instructions </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is intended for intravenous administration using sterile equipment. </item>
                     <item>
                        <caption>•</caption>Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. </item>
                     <item>
                        <caption>•</caption>Set the vent to the closed position on a vented intravenous administration set to prevent air embolism. </item>
                     <item>
                        <caption>•</caption>Use a dedicated line without any connections to avoid air embolism. </item>
                     <item>
                        <caption>•</caption>Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container. </item>
                     <item>
                        <caption>•</caption>Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged. </item>
                     <item>
                        <caption>•</caption>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is compatible with blood or blood components. It may be administered prior to or following the infusion of blood through the same administration set (i.e., as a priming solution), added to or infused concurrently with blood components, or used as a diluent in the transfusion of packed erythrocytes. PLASMA-LYTE 148 Injection and 0.9% Sodium Chloride Injection, USP are equally compatible with blood or blood components.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Dosing Information</content>
                  </paragraph>
                  <paragraph>The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Introduction of Additives </content>
                  </paragraph>
                  <paragraph>Additives may be incompatible. </paragraph>
                  <paragraph>Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available. </paragraph>
                  <paragraph>If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use. Do not store solutions containing additives. Discard any unused portion.</paragraph>
               </text>
               <effectiveTime value="20190805"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_inv-78dacc60-0a60-4aff-82fc-d6b63039eef5">
               <id root="e2d8a89c-4214-498e-9245-95ff0536bdd7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in VIAFLEX plastic containers is available as shown below:</paragraph>
                  <table width="100%">
                     <col width="24%"/>
                     <col width="27%"/>
                     <col width="33%"/>
                     <thead>
                        <tr>
                           <th align="center" styleCode="Botrule Toprule " valign="top">
                              <content styleCode="bold">Code</content>
                           </th>
                           <th align="center" styleCode="Botrule Toprule " valign="top">
                              <content styleCode="bold">Size</content>
                              <br/>
                              <content styleCode="bold">(mL)</content>
                           </th>
                           <th align="center" styleCode="Botrule Toprule " valign="top">
                              <content styleCode="bold">NDC</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule " valign="top">
                              <paragraph>2B2534</paragraph>
                           </td>
                           <td styleCode="Toprule " valign="top">
                              <paragraph>1000</paragraph>
                           </td>
                           <td styleCode="Toprule " valign="top">
                              <paragraph>NDC 0338-0179-04</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>2B2533</paragraph>
                           </td>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>500</paragraph>
                           </td>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>NDC 0338-0179-03</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.</paragraph>
               </text>
               <effectiveTime value="20170828"/>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_inv-0cc07f49-05e8-4f61-82e2-5f3f2a18de5d">
               <id root="6800fa0f-3c46-45a3-a3c1-c4995e6c20d0"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>DIRECTIONS FOR USE OF VIAFLEX PLASTIC CONTAINER</title>
               <text>
                  <paragraph> For Information on Risk of Air Embolism – see <linkHtml href="#i4i_precautions_id_inv-b4b9873c-c383-4f8d-bdcb-6b0c69546b9a">PRECAUTIONS</linkHtml>
                  </paragraph>
               </text>
               <effectiveTime value="20170828"/>
               <component>
                  <section ID="i4i_section_id_inv-99451f88-6e11-4594-8705-133bbb441471">
                     <id root="d377e469-df80-48b1-9a3f-83480fbd2a4f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>To Open</title>
                     <text>
                        <paragraph>Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below.</paragraph>
                     </text>
                     <effectiveTime value="20090610"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_inv-841163db-80f2-40bd-bc49-662ec438b058">
                     <id root="f6d78347-bb50-4632-a428-add100863322"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Preparation for Administration</title>
                     <text>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Suspend container from eyelet support.</item>
                           <item>
                              <caption>2.</caption>Remove protector from outlet port at bottom of container.</item>
                           <item>
                              <caption>3.</caption>Attach administration set. Refer to complete directions accompanying set.</item>
                        </list>
                     </text>
                     <effectiveTime value="20170828"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_inv-25b72fb7-58d7-464d-b5f2-be9e7c79d578">
                     <id root="4ab301e5-5194-44db-8d43-2c9f28dd5ff9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>To Add Medication</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">To add medication before solution administration</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Prepare medication site.</item>
                           <item>
                              <caption>2.</caption>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.</item>
                           <item>
                              <caption>3.</caption>Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To add medication during solution administration</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Close clamp on the set.</item>
                           <item>
                              <caption>2.</caption>Prepare medication site.</item>
                           <item>
                              <caption>3.</caption>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.</item>
                           <item>
                              <caption>4.</caption>Remove container from IV pole and/or turn to an upright position.</item>
                           <item>
                              <caption>5.</caption>Evacuate both ports by squeezing them while container is in the upright position.</item>
                           <item>
                              <caption>6.</caption>Mix solution and medication thoroughly.</item>
                           <item>
                              <caption>7.</caption>Return container to in use position and continue administration.</item>
                        </list>
                     </text>
                     <effectiveTime value="20170828"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_aa64805b-77c1-4c6e-b441-51baead44c53">
               <id root="09b8fd20-0249-45e6-be40-a2ff8dc8d9ee"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare Corporation</content>
                     <br/>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>Printed in USA</paragraph>
                  <paragraph>07-19-00-1558</paragraph>
                  <paragraph>Rev. August 2019</paragraph>
                  <paragraph>Baxter, Plasma-Lyte, Viaflex, and PL 146 are trademarks of Baxter International Inc.</paragraph>
               </text>
               <effectiveTime value="20190805"/>
            </section>
         </component>
         <component>
            <section ID="i4i_Principal_display_panel_id_671c0c21-76c4-4072-b174-01acad17649c">
               <id root="bc35a0c8-449a-4f18-9287-e3ca9f23d6e7"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia ID="id460" referencedObject="id_6a57274b-af78-47fd-a779-ac36a093c602">
                     <caption>500 mL Container Label </caption>
                  </renderMultiMedia>
                  <paragraph>500 mL Container Label </paragraph>
                  <paragraph>
                     <content styleCode="bold">2B2533 </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-0179-03 </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PLASMA-LYTE 148</content>
                     <br/>
                     <content styleCode="bold">Injection  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(Multiple Electrolytes Injection </content>
                     <br/>
                     <content styleCode="bold">Type 1 USP) </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mL </content>
                  </paragraph>
                  <paragraph>EACH 100 mL CONTAINS 526 mg SODIUM CHLORIDE USP 502 mg<br/>SODIUM GLUCONATE USP 368 mg SODIUM ACETATE TRIHYDRATE<br/>USP 37 mg POTASSIUM CHLORIDE USP 30 mg MAGNESIUM<br/>CHLORIDE USP pH ADJUSTED WITH HYDROCHLORIC ACID pH 5.5<br/>(4.0 TO 8.0) mEq/L SODIUM 140 POTASSIUM 5 MAGNESIUM 3<br/>CHLORIDE 98 ACETATE 27 GLUCONATE 23 OSMOLARITY 294<br/>mOsmol/L (CALC) STERILE NONPYROGENIC SINGLE DOSE CONTAINER<br/>ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH PHARMACIST IF<br/>AVAILABLE WHEN INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUE<br/>MIX THOROUGHLY DO NOT STORE DOSAGE INTRAVENOUSLY AS<br/>DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE AND<br/>INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITY DISCARD IF<br/>LEAKS ARE FOUND MUST NOT BE USED IN SERIES CONNECTIONS DO<br/>NOT USE UNLESS SOLUTION IS CLEAR <content styleCode="bold">RX ONLY </content>STORE UNIT IN<br/>MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE (25<content styleCode="bold">°</content>C/77<content styleCode="bold">°</content>F)<br/>UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT</paragraph>
                  <paragraph>VIAFLEX CONTAINER<br/>PL 146 PLASTIC</paragraph>
                  <paragraph>FOR PRODUCT INFORMATION<br/>1-800-933-0303</paragraph>
                  <paragraph>BAXTER PLASMA-LYTE VIAFLEX<br/>AND PL 146 ARE TRADEMARKS OF<br/>BAXTER INTERNATIONAL INC</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter logo</content>
                     </content>
                     <br/>
                     <content styleCode="bold">BAXTER HEALTHCARE CORPORATION </content>
                     <br/>DEERFIELD IL 60015 USA<br/>MADE IN USA</paragraph>
                  <renderMultiMedia ID="id525" referencedObject="id_a7afbc56-6fd6-44b9-bde8-46363bde61a5">
                     <caption>1000 mL Container Label </caption>
                  </renderMultiMedia>
                  <paragraph>1000 mL Container Label </paragraph>
                  <paragraph>
                     <content styleCode="bold">LOT</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">EXP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2B2534 </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-0179-04 </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Plasma-Lyte </content>
                     <br/>
                     <content styleCode="bold">148 Injection </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(Multiple Electrolytes </content>
                     <br/>
                     <content styleCode="bold">Injection Type 1 USP) </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1000 mL </content>
                  </paragraph>
                  <paragraph>EACH 100 mL CONTAINS 526 mg SODIUM CHLORIDE USP 502<br/>mg SODIUM GLUCONATE USP 368 mg SODIUM ACETATE<br/>TRIHYDRATE USP 37 mg POTASSIUM CHLORIDE USP 30 mg<br/>MAGNESIUM CHLORIDE USP pH ADJUSTED WITH HYDROCHLORIC<br/>ACID pH 5.5 (4.0 TO 8.0) mEq/L SODIUM 140 POTASSIUM 5<br/>MAGNESIUM 3 CHLORIDE 98 ACETATE 27 GLUCONATE 23<br/>OSMOLARITY 294 mOsmol/L (CALC) STERILE NONPYROGENIC<br/>SINGLE DOSE CONTAINER ADDITIVES MAY BE INCOMPATIBLE<br/>CONSULT WITH PHARMACIST IF AVAILABLE WHEN INTRODUCING<br/>ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT<br/>STORE DOSAGE INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN<br/>SEE DIRECTIONS CAUTIONS SQUEEZE AND INSPECT INNER BAG<br/>WHICH MAINTAINS PRODUCT STERILITY DISCARD IF LEAKS ARE<br/>FOUND MUST NOT BE USED IN SERIES CONNECTIONS DO NOT USE<br/>UNLESS SOLUTION IS CLEAR RX ONLY STORE UNIT IN MOISTURE<br/>BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C/77°F) UNTIL<br/>READY TO USE AVOID EXCESSIVE HEAT SEE INSERT</paragraph>
                  <paragraph>VIAFLEX CONTAINER PL 146 PLASTIC</paragraph>
                  <paragraph>BAXTER PLASMA-LYTE VIAFLEX AND PL 146 ARE<br/>TRADEMARKS OF BAXTER INTERNATIONAL INC</paragraph>
                  <paragraph>FOR PRODUCT INFORMATION 1-800-933-0303</paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter logo</content>
                     <br/>
                     <content styleCode="bold">BAXTER HEALTHCARE CORPORATION</content>
                     <br/>DEERFIELD IL 60015 USA<br/>MADE IN USA</paragraph>
               </text>
               <effectiveTime value="20190805"/>
               <component>
                  <observationMedia ID="id_6a57274b-af78-47fd-a779-ac36a093c602">
                     <text>Package Label - Container 500 mL</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="id_a7afbc56-6fd6-44b9-bde8-46363bde61a5">
                     <text>Package Label - Container 1000 mL</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>